In addition, Yue et al. showed that inhibition of TGF-β using galunisertib, an ALK5 (TGFBR1) inhibitor, reduces, but does not abrogate, myelofibrosis in the clinically relevant MPLW515L model of MPN. Here, TGFBR1 is linked to myeloproliferative disorder.